Loading…
Ken GriffinReduced
Citadel Advisors · Q2 2026
$2.7M
168.13K shares · 0.0% of portfolio
Takeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd (TAK) is listed on NYSE and classified in Drug Manufacturers - Specialty & Generic, part of the Healthcare sector. It is headquartered in Chuo, Japan and has 47,029 employees. The company is worth $65.04B. Revenue was ¥4.51T in fiscal 2026, down 1.7% from the year before. It reported a net loss of ¥152.39B. The share price is within 3% of its 52-week high. It pays a dividend yielding 3.05%. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Renaissance Technologies, at $41.17M. In that quarter, 4 of them opened or added to the position and 2 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Revenue, debt and profit are in JPY, the currency the company reports in — not converted to dollars. Dividends are in dollars.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +47.3% over 5Y.
today you would have $1,498.66▲ +49.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Year-end price | $19.67 | $15.59 | $13.24 | $14.27 | |
| EPS | ¥59.82 | ¥33.62 | ¥45.58 | ¥100.97 | |
| Dividend yield | — | — | 2.17% | 4.67% | — |
| Profit margin | 2.87% | -3.38% | 2.36% | 3.38% | 7.87% |
| ROE | 1.77% | -2.05% | 1.56% |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CORCencora, Inc. | $338.48 | 25.3x | 21.2x | 0.71% | 96.87% | $64.59B |
| BSXBoston Scientific Corp | $46.01 | 18.0x | 2.7x | 0.00% | 15.34% | $66.68B |
| CAHCardinal Health Inc | $255.64 | 35.4x | — | 0.81% | — | $59.2B |
| NTRANatera, Inc. | $401.37 |
| 1.98% |
| 4.99% |
This company reports in JPY, and the stock trades in dollars. P/E, P/S, P/B and payout would divide dollars by JPY, so they are not shown; EPS is in JPY. Margin, ROE and dividend yield do not depend on the currency.
Median of the years shown; P/E years above 200x are left out.
Dividend growing 0.0% a year against a 7.0% required return, from the stock’s beta.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
1 methods answered, across 1 families.
Room for errors in the reported numbers.
-76.2% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| — |
| 31.6x |
| 0.00% |
| -12.54% |
| $57.86B |
| ARGXArgenx SE | $875.76 | 34.0x | 7.4x | 0.00% | 23.64% | $55.07B |
| BDXBecton Dickinson & Co | $200.42 | 46.6x | 2.2x | 2.10% | 6.61% | $54.59B |